Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations.

ingentiumby ingentium

In Parkinson's Disease Literature.

Publication date: Mar 22, 2025

Traditional advanced therapies in Parkinson’s disease (PD) with motor fluctuations and dyskinesias like continuous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel (LCIG), levodopa-carbidopa entacapone intestinal gel (LECIG), or deep brain stimulation (DBS) have played a central role in managing therapy-related complications. Recently, continuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) has emerged as a novel therapeutic option. This manuscript provides insights from one year of real-world experience with CSFLI, addressing critical questions that clinicians face when selecting the most appropriate therapy for advanced PD. Our discussion centers on key considerations for patient selection, exploring which individuals may benefit more from CSFLI compared to other device-aided therapies. We highlight CSFLI’s advantages in flexibility and ease of use but also consider limitations, particularly its side effects, such as skin-related issues. Recommendations are presented on how to prevent and manage these adverse effects to maximize patient compliance and therapeutic success. Additionally, the paper examines strategies for optimizing concurrent oral medications when combined with CSFLI, providing guidance on balancing pump infusion with necessary adjunctive oral treatments.

Open Access PDF

Concepts Keywords
Clinicians Advanced Treatment
Continuous Foslevodopa/Foscarbidopa
Drugs Motor Fluctuations
Parkinson Parkinson’s disease
Vienna

Semantics

Type Source Name
disease MESH Parkinson’s disease
disease MESH dyskinesias
drug DRUGBANK Apomorphine
drug DRUGBANK Levodopa
drug DRUGBANK Carbidopa
drug DRUGBANK Entacapone
disease MESH complications
drug DRUGBANK Spinosad
disease MESH erythema
disease MESH cellulitis
drug DRUGBANK Iron
drug DRUGBANK Domperidone
disease MESH hyposmia
drug DRUGBANK Coenzyme M
disease MESH depression
disease MESH anxiety
disease MESH breathlessness
disease MESH hallucinations
disease MESH psychosis
pathway REACTOME Release
drug DRUGBANK Methylcellulose
drug DRUGBANK Polyethylene glycol
drug DRUGBANK Methionine
disease MESH edema
disease MESH hemorrhage
disease MESH infection
drug DRUGBANK Morphine
drug DRUGBANK Mometasone furoate
disease MESH inflammation
drug DRUGBANK Opicapone
drug DRUGBANK Amino acids
drug DRUGBANK Amantadine
drug DRUGBANK Trestolone
disease MESH tremor
disease MESH camptocormia
disease MESH abnormalities
drug DRUGBANK Safinamide
drug DRUGBANK Clozapine
disease MESH syndrome
disease MESH orthostatic hypotension
drug DRUGBANK Midodrine
drug DRUGBANK Droxidopa
disease MESH dysphagia
disease MESH symptom worsening
disease MESH confusion
disease MESH myoclonus
disease MESH dementia
disease MESH thrombosis
drug DRUGBANK Dopamine
disease MESH hydrocephalus
disease MESH mild cognitive impairment
disease MESH contraindication
disease MESH impulse control disorders
disease MESH sweating
disease MESH sleep disorders
disease MESH Chronic Disease
pathway REACTOME Reproduction
disease MESH Panniculitis
drug DRUGBANK Bismuth subgallate
disease MESH movement disorder
disease MESH parkinsonism
pathway KEGG Parkinson disease
drug DRUGBANK L-Leucine
disease MESH insomnia
drug DRUGBANK Rotigotine
drug DRUGBANK Sarizotan
drug DRUGBANK Lenomorelin
drug DRUGBANK Diethylstilbestrol
disease MESH Neuroleptic malignant syndrome
disease MESH posture
disease MESH emergencies
drug DRUGBANK Methyl isocyanate
drug DRUGBANK Isoxaflutole
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
drug DRUGBANK L-Phenylalanine
disease MESH palsy
disease MESH restless legs syndrome
disease MESH hyperpyrexia

Original Article

(Visited 5 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *